Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.

Conclusion: Brentuximab vedotin increased the risk of certain AEs in lymphoma patients. PMID: 31955620 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31955620?dopt=Abstract

Source: Expert Opinion on Drug Safety - January 22, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research